Boston Scientific Corporation priced $3 billion in US dollar-denominated senior notes and €4.25 billion in euro-denominated senior and floating rate notes on November 19, 2026, according to company announcements.
The proceeds are earmarked for the cash consideration in the acquisition of Penumbra, Inc., with closing scheduled for December 1, 2026. The company stated that the offerings are not conditioned on completion of the acquisition.
USD Note Details
The US dollar offering comprises four tranches:
- $1 billion of 5.375% Senior Notes due 2029
- $750 million of 5.500% Senior Notes due 2031
- $750 million of 5.750% Senior Notes due 2033
- $500 million of 5.875% Senior Notes due 2036
Euro Note Details
The euro offering, priced by American Medical Systems Europe B.V., Boston Scientific's indirect wholly owned finance subsidiary, includes six tranches:
- €500 million of Floating Rate Notes due 2028
- €500 million of 3.875% Senior Notes due 2028
- €750 million of 4.125% notes due 2030
- €750 million of 4.500% notes due 2034
- €1 billion of 4.750% notes due 2038
- €750 million of 5.125% notes due 2046
The Euro Notes will be fully and unconditionally guaranteed by Boston Scientific.
Use of Proceeds and Financing Structure
Boston Scientific plans to combine the note proceeds with short-term borrowings and borrowings under its credit agreements, along with cash on hand, to finance the acquisition.
Most note series include a special mandatory redemption provision at 101% of principal plus accrued and unpaid interest if the Penumbra acquisition does not close by the applicable end date or if the company notifies the trustee that it will not pursue the deal.
BofA Securities, Inc., Citigroup Global Markets Inc., and J.P. Morgan Securities LLC served as joint book-running managers for the USD offering.
About Boston Scientific
Boston Scientific describes itself as a global medical technology company based in Marlborough, Massachusetts, with over 45 years of history. The company is listed on the NYSE under the ticker BSX and develops devices and therapies for cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.


